KIORA PHARMACEUTICALS, INC. Sale of Stock, Consideration Received on Transaction
KIORA PHARMACEUTICALS, INC. (KPRX) had Sale of Stock, Consideration Received on Transaction of $5.60 million as of 2023-06-06, per its 10-K filed 2025-03-25.
Financial Statements › Notes › Equity
us-gaap:SaleOfStockConsiderationReceivedOnTransaction · last filed 2025-03-25
- 2023-06-06: Sale of Stock, Consideration Received on Transaction $5.60M.
- 2017-02-21: Sale of Stock, Consideration Received on Transaction $3.29M; Sale of Stock, Consideration Received on Transaction 1 month $3.29M.
- 2016-05-24: Sale of Stock, Consideration Received on Transaction 1 month $3.29M.
| Period end | Sale of Stock, Consideration Received on Transaction | Sale of Stock, Consideration Received on Transaction 1 month |
|---|---|---|
| 2023-06-06 | $5.60M 10-K · filed 2025-03-25 | |
| 2017-02-21 | $3.29M 10-Q · filed 2019-08-08 | $3.29M 10-Q · filed 2019-05-08 |
| 2016-05-24 | $3.29M 10-Q · filed 2018-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |